Line probe assay for simultaneous detection of hepatitis B virus wild-type motif, lamivudine, telbivudine, emtricitabine, adefovir, and entecavir resistance-associated mutations.
Features & Benefits
Earliest detection of mutants:
Highly sensitive detection at single nucleotide level of mixtures of wild-type and mutants, identifying the appearance of mutants earlier than sequencing and viral load assays
Lower limit of detection of 990 copies/ml
Allowing rapid and effective HBV suppression by early adoption to the most suited therapy
All the necessary information in one assay:
Allows simultaneous detection of all clinically relevant HBV polymerase wild-type and drug-induced mutations associated with lamivudine, emtricitabine, telbivudine, adefovir and tenofovir resistance as well as known compensatory mutations (codons 80, 173, 180, 181, and 204)
Identifies amino acid changes in the overlapping reading frame of HBsAg (codons 171, 172, 195, 196, 198, and 199)
Optimised for 8 known HBV genotypes (A-H)
Low chance of errors and limited hands-on time:
Easy to perform and robust assay
Amplicon can also be used for INNO-LIPA HBV GT
Fully automated processing of the strips possible with TENDIGO®, Auto-LIPA™ 48 and AutoBlot 3000H.
Objective and automated reading and interpretation of strips possible using LiRAS® for Infectious Diseases.